ReviewChemical science2026
The hidden language of gut-derived lipopolysaccharides: fine chemistry, huge immunological consequences.
Review in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structure matters: commensalFrontiers in cellular neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipopolysaccharides (LPSs) from Gram-negative bacteria are traditionally viewed as potent "endotoxins" recognized by the immune system and capable of triggering robust inflammation. However, increasing evidence from gut commensals is dismantling this one-dimensional view. The gastrointestinal tract is indeed the major reservoir of LPSs, owing to the dense Gram-negative community inhabiting the small and large intestine, with total weight in healthy individuals estimated to exceed one gram. This necessarily means that the mere presence of LPSs cannot be directly linked to inflammation. Moreover, chronic exposure to low-potency or atypical LPSs can recalibrate innate immunity, fostering tolerance or, conversely, failing to provide adequate tonic stimulation and thereby predisposing the system to aberrant activation. Understanding this delicate balance and the structural and cellular mechanisms that sustain it, is essential to interpret the immunological impact of the gut LPSs in health and disease. In this Perspective, we highlight recent advances revealing the remarkable chemical diversity of commensal-derived LPSs and illustrate how subtle variations in LPS lipid A acylation and phosphorylation, core oligosaccharide architecture, O-antigen composition, and overall supramolecular organization profoundly rewire receptor usage and downstream immune outcomes. These insights underscore the enormous, still largely untapped potential of gut LPS chemistry to reveal unifying structural hallmarks that distinguish inflammatory, tolerogenic, and immunologically "tuned" features. Although fragments of this logic are beginning to emerge, a comprehensive framework remains urgently needed. Decoding the chemical language adopted by LPSs in the gut will be essential to reclassify LPSs not merely as dangerous molecules, but as a potential source of immunomodulators and as a blueprint for next-generation tools enabling precision control of host-microbe interactions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.